Metformin sensitises hepatocarcinoma cells to methotrexate by targeting dihydrofolate reductase

Metformin sensitises hepatocarcinoma cells to methotrexate by targeting dihydrofolate reductase

Abstract Metformin, the first-line drug for type II diabetes, has recently been considered an anticancer agent. However, the molecular target and underlying mechanism of metformin’s anti-cancer effects remain largely unclear. Herein, we report that metformin treatment increases the sensitivity of he...

Full description

Bibliographic Details
Main Authors: Yinghui Wang, Hui Lu, Linchong Sun, Xin Chen, Haoran Wei, Caixia Suo, Junru Feng, Mengqiu Yuan, Shengqi Shen, Weidong Jia, Ying Wang, Huafeng Zhang, Zijun Li, Xiuying Zhong, Ping Gao
Format: Article
Language:English
Published: Nature Publishing Group 2021-10-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-021-04199-1

Internet

https://doi.org/10.1038/s41419-021-04199-1

Similar Items